SINTX Technologies (SINT) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
12 Jun, 2026Executive summary
Revenue for Q2 2024 increased 61% year-over-year to $0.86 million, driven by new orders for silicon nitride aerospace components and government contracts in both Salt Lake City and Maryland operations.
Net loss for Q2 2024 was $2.2 million, a 10% improvement from the $2.5 million loss in Q2 2023, reflecting higher revenue and reduced operating expenses.
The company implemented a 1-for-200 reverse stock split in May 2024 to regain Nasdaq compliance and subsequently received confirmation of compliance with the $1.00 minimum bid price requirement.
In August 2024, a company-wide workforce reduction was approved, reducing headcount from 40 to 23, and the decision was made to cease efforts to make the armor plant operational, resulting in an expected $4.5 million impairment charge.
Financial highlights
Product revenue for Q2 2024 was $0.38 million, up 61% year-over-year; grant and contract revenue was $0.48 million, up 76%.
Gross profit for Q2 2024 increased 57% to $0.35 million; cost of revenue rose 115% to $0.22 million.
Operating expenses for Q2 2024 decreased 14% year-over-year to $3.3 million, with R&D down 22%, G&A down 8%, and sales/marketing down 17%.
Net loss per share (basic) for Q2 2024 was $(3.49), compared to $(120.63) in Q2 2023, reflecting the reverse split.
Cash and cash equivalents as of June 30, 2024, were $4.6 million, up from $3.3 million at year-end 2023.
Outlook and guidance
Management expects continued investment in R&D to provide additional revenue opportunities, with a focus on expanding silicon nitride applications beyond spinal fusion and into new advanced ceramic materials.
The company is actively seeking additional capital and acknowledges that existing resources are insufficient to fund all planned development and commercialization activities.
Strategic focus is shifting to core business areas following the shutdown of the armor plant and workforce reduction.
Latest events from SINTX Technologies
- Silicon nitride implants disrupt extremity care with infection resistance and rapid market adoption.SINT
LD Micro Invitational XVI15 Jun 2026 - Q1 2025 net loss was $2.3M, but cash nearly doubled as focus shifted to medical devices.SINT
Q1 202512 Jun 2026 - FDA clearance, first product revenue, and cost reductions drive improved results.SINT
Q3 202512 Jun 2026 - 2024 revenue rose 10% to $2.9M, but net loss increased to $11.0M amid restructuring.SINT
Q4 202412 Jun 2026 - Annual meeting to vote on directors, auditor, compensation, and new equity plan.SINT
Proxy filing12 Jun 2026 - Revenue fell sharply as the company pivots to higher-margin medical devices, but liquidity risks persist.SINT
Q4 202512 Jun 2026 - Shareholders will vote on director election, auditor, executive pay, and expanding the equity plan.SINT
Proxy filing12 Jun 2026 - Q3 2024 net loss widened due to a $4.5M impairment and workforce reduction amid a strategic review.SINT
Q3 202412 Jun 2026 - Revenue fell 82% year-over-year as the company pivots to biomedical devices amid ongoing losses.SINT
Q2 202512 Jun 2026